June 2019 - Volume 3 - Issue - Contributor Index

Author:
Iaccarino, S.

NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.: S1620

Candoni, A.; Lazzarotto, D.; Curti, A.; More

HemaSphere. 3:748, June 2019.

Author:
Iacoboni, G.
Author:
Iacobucci, I.

A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1: PS997

Cerchione, C.; Guadagnuolo, V.; Papayannidis, C.; More

HemaSphere. 3:448-449, June 2019.

Author:
Iannitto, E.

RETROSPECTIVE REAL-LIFE STUDY OF BRENTUXIMAB VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE IN REFRACTORY OR MULTIPLE RELAPSED HODGKIN LYMPHOMA: PF474

Iannitto, E.; Romano, A.; Scalzulli, P. R.; More

HemaSphere. 3:188-189, June 2019.

Author:
Ianotto, J.-C.

REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE: PF757

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3:332-333, June 2019.

Author:
Ibarra, M.
Author:
Ibatici, A.

IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY: PF375

Mauro, F. R.; Molica, S.; Paoloni, F.; More

HemaSphere. 3:139, June 2019.

THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE: PS1152

Innocenti, I.; Morelli, F.; Autore, F.; More

HemaSphere. 3:522-523, June 2019.

Author:
Iberl, S.
Author:
Ibrahiem, G. A.
Author:
ibrahim, M. A.
Author:
Ibrahim, R.

MOLECULAR PROFILING OF PRIMARY BONE LYMPHOMA'S REVEALS FREQUENT MUTATIONS IN EZH2 AND OTHER EPIGENETIC GENES: IMPLICATIONS FOR TARGETED TREATMENT: PF519

Ibramoglu, Suleiman M.; de Groen, R. A.; van Eijk, R.; More

HemaSphere. 3:212, June 2019.

Author:
Ichikawa, S.

LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL: PF348

Röth, A.; Nagy, Z.; de Latour, Peffault R.; More

HemaSphere. 3:125-126, June 2019.

Author:
Ichiki, T.
Author:
Ichinohe, T.
Author:
Ida, Maria B.

CLUSTER ANALYSIS IDENTIFIES A SPECIFIC IMMUNOPHENOTYPIC PROFILE ASSOCIATED WITH HIGH RISK OF PRIMARY INDUCTION FAILURE AND SHORTER OVERALL AND DISEASE-FREE SURVIVAL IN NPM1-MUTATED AML: PF229

Piccini, M.; Bencini, S.; Ida, Maria B.; More

HemaSphere. 3:66-67, June 2019.

Author:
Idowu, M.

SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW-UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES: S853

Liles, D.; Shah, N.; Scullin, B.; More

HemaSphere. 3:380-381, June 2019.

Author:
idris, N.
Author:
Idris, S. F.
Author:
Idrissova, E.
Author:
Idrobo, H.
Author:
Ifrah, N.
Author:
Igarashi, T.

EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY: PF184

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3:44, June 2019.

Author:
Iglesias, T.

GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA: S113

Fagnan, A.; Piqué Borràs, Riera M.; Ignacimouttou, C.; More

HemaSphere. 3:8-9, June 2019.

RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL: PF151

Laurent, A. P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3:28, June 2019.

Author:
Ignatieva, S.

INVASIVE FUNGAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS WITH HODGKIN'S LYMPHOMA: PS1285

Popova, M.; Rogacheva, Y.; Volkova, A.; More

HemaSphere. 3:588, June 2019.

Author:
Ignatova, K.
Author:
Ignatyeva, S.
Author:
Iida, S.

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK: PF591

Dimopoulos, M. A.; San-Miguel, J.; White, D.; More

HemaSphere. 3:247-248, June 2019.

RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA: S823

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3:364, June 2019.

COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN: PS1367

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3:624-625, June 2019.

Author:
Iino, M.

CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012): PS1263

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3:578, June 2019.

Author:
Iizuka, K.
Author:
Iizuka, Y.
Author:
Ijurko, C.
Author:
Ikebe, E.
Author:
Ikeda, A.

SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW-UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES: S853

Liles, D.; Shah, N.; Scullin, B.; More

HemaSphere. 3:380-381, June 2019.

Author:
Ikeda, K.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

Author:
Ikeda, T.
Author:
Ikezoe, T.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY: PS1115

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3:504-505, June 2019.

Author:
Ikuta, K.
Author:
Iland, H.
Author:
Ilari, C.

PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: PF365

Raponi, S.; Ilari, C.; Della Starza, I.; More

HemaSphere. 3:134-135, June 2019.

Author:
Ilariucci, F.

IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY: PF375

Mauro, F. R.; Molica, S.; Paoloni, F.; More

HemaSphere. 3:139, June 2019.

Author:
Ilhan, Ç.
Author:
Ilhan, O.

CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA: PB1933

Saydam, G.; Ünal, A.; Kurtoglu, E.; More

HemaSphere. 3:879, June 2019.

Author:
Iliakis, T.

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS: PS1258

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3:575, June 2019.

Author:
Ilic, I.

LONG TERM FOLLOW-UP OF MAINTENANCE THERAPY WITH INTEREFRON ALPHA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA PATIENTS-SINGLE CENTER EXPERIENCE: PB2175

Batinic, J.; Bašic-Kinda, S.; Pulanic, D.; More

HemaSphere. 3:976, June 2019.

Author:
Ilieva, M.
Author:
Illert, A. L.
Author:
Illes, A.

FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY: S820

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3:362-363, June 2019.

THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS: PS1070

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3:484-485, June 2019.

MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS): PS1457

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 3:670-671, June 2019.

Author:
Illés, Á.

IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY: PF294

Morschhauser, F.; Feugier, P.; Flinn, I. W.; More

HemaSphere. 3:99, June 2019.

Author:
Illidge, T.

THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS: PS1070

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3:484-485, June 2019.

Author:
Illig, T.
Author:
Illman, J.
Author:
Iltar, U.
Author:
Ilyasov, R.

EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION: PS1104

Melikyan, A.; Egorova, E.; Pustovaya, E.; More

HemaSphere. 3:500, June 2019.

Author:
Im, J.

POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY: PS1530

Mehta, R.; Bassett, R.; Olson, A.; More

HemaSphere. 3:706, June 2019.

RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS: PS1561

Khouri, I.; Milton, D.; Young, K.; More

HemaSphere. 3:720, June 2019.

Author:
Im, K.
Author:
Imada, K.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

Author:
Imagawa, J.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

Author:
Imai, T.
Author:
Imamura, M.
Author:
Imawari, M.
Author:
Imbergamo, S.

NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.: S1620

Candoni, A.; Lazzarotto, D.; Curti, A.; More

HemaSphere. 3:748, June 2019.

Show: